NASDAQ:SVRA Savara Q1 2025 Earnings Report $5.37 0.00 (0.00%) As of 04:00 PM Eastern ProfileEarnings HistoryForecast Savara EPS ResultsActual EPS-$0.14Consensus EPS -$0.12Beat/MissMissed by -$0.02One Year Ago EPSN/ASavara Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ASavara Announcement DetailsQuarterQ1 2025Date8/13/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsSavara's Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Savara Earnings HeadlinesAnalysts Set Savara Inc. (NASDAQ:SVRA) PT at $10.14August 27, 2026 | americanbankingnews.comSavara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis ...August 24, 2026 | uk.finance.yahoo.comAnthropic’s confidential SEC filing — and the public ticker that holds itAnthropic filed confidentially for an IPO, and its annualized revenue run rate reportedly surged to $65 billion in July - seven times last year's pace. One public ticker reportedly holds Anthropic alongside $190 billion Databricks and $61 billion Anduril - three private-company catalysts in a single brokerage trade. Alexander Green believes the next major catalyst could arrive as early as September 29, when The AI Conference begins in San Francisco.September 4 at 1:00 AM | The Oxford Club (Ad)Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026August 24, 2026 | businesswire.comSavara Inc. (SVRA) Latest Press Releases & Corporate News - Yahoo FinanceAugust 20, 2026 | finance.yahoo.comSavara: High Potential Binary Bet Cruising To PDUFA After 3 Month Speed BumpAugust 5, 2026 | seekingalpha.comSee More Savara Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Savara? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Savara and other key companies, straight to your email. Email Address About SavaraSavara (NASDAQ:SVRA) (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need. The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant. In addition, Savara has in-licensed Brensocatib, a dipeptidyl peptidase 1 (DPP-1) inhibitor originally developed by AstraZeneca, which is being evaluated in clinical trials for non-cystic fibrosis bronchiectasis (NCFBE) and nontuberculous mycobacterial (NTM) lung infections. These programs reflect the company’s strategy of leveraging existing pharmacological data to streamline development in orphan respiratory indications. Founded in 2013 and headquartered in Austin, Texas, Savara conducts its research and development activities primarily in North America and Europe. The company collaborates with academic institutions, patient advocacy groups and strategic partners to support clinical trial execution, regulatory interactions and eventual commercialization planning. Savara’s management team brings together expertise in drug development, regulatory affairs and respiratory medicine, all aimed at transforming care for patients with life-threatening pulmonary disorders.View Savara ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Snowflake’s AI Momentum Is Forcing a Fresh Look at the StockAeroVironment’s $465 Million Army Laser Win Expands Its Counter-Drone OpportunityFB Financial's Southern Expansion and Buybacks Drive Analyst OptimismRetail Earnings Just Exposed a Bigger Divide in the U.S. Consumer EconomyAccelerant’s Take-Private Deal Raises a Bigger Question for Insurance StocksDefense Stocks Are Pulling Back as Their Navy Tailwinds Get StrongerThe Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story Upcoming Earnings Adobe (9/10/2026)Oracle (9/10/2026)FedEx (9/17/2026)Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
